 |
|
|
| |
QUALITATIVE FINDINGS FROM A HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY TO EXPLORE PERSPECTIVES OF HEALTHCARE STAFF ON EARLY IMPLEMENTATION OF CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING INJECTABLE IN THE UNITED STATES (CUSTOMIZE)
|
| |
| |
IDWeek 2020 Oct 21-25 virtual
Reported by Jules Levin
Maggie Czarnogorski,1 Cindy Garris,1 Paul Wannamaker,1 Ronald D'Amico,1 Carolyn Selenski,2 Will Williams,2 Colleen McHorney,3 Larissa Stassek,3 Michael Wohlfeiler,4 Gary Sinclair,5 Leandro Mena,6 David Margolis1
1ViiV Healthcare, Research Triangle Park, NC, USA; 2GlaxoSmithKline, Collegeville, PA, USA; 3Evidera, Bethesda, MD, USA; 4AIDS Healthcare Foundation, Los Angeles, CA, USA; 5Prism Health North Texas, Dallas, TX, USA; 6University of Mississippi Medical Center, Jackson, MS, USA
References
1. Swindells et al. N Engl J Med. 2020;382:1112-1123. 2. Orkin et al. N Engl J Med. 2020;382:1124-1135. 3. Consolidated Framework for Implementation Research. Tools and templates. https://cfirguide.org/tools/tools-and-templates. Accessed August 17, 2020.
|
| |
|
|
|
|
|
